|

Apixaban Clinical Trials

11 actively recruiting trials across 5 locations

Also known as: 1-(4methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-4,5,6,7-tetrahydro-1H-pyrazolo[3,4c]pyridine-3-carboxamide, B01A F02, C25H25N5O4, Eliquis, Poltixa

Other6 trials

AntiCoagulation Versus AcetylSalicylic Acid After Transcatheter Aortic Valve Implantation
Phase 3
COmparison of Bleeding Risk Between Rivaroxaban and Apixaban in Patients With Atrial Fibrillation
Phase 4
Comparison of the Effects of Apixaban on Thrombin Generation in Patients With de Novo Multiple Myeloma
N/A
Pharmacokinetics of Apixaban in Peritoneal Dialysis
Reduced-Dose Apixaban and Rivaroxaban Versus Low-Molecular-Weight Heparin in Patients With Hematologic Malignancies
N/A
Secondary Prevention of VTE in Patients With Cancer and Catheter-Related Upper Extremity Deep Vein Thrombosis
Phase 4

Birmingham, Alabama1 trial

Anticoagulation in ICH Survivors for Stroke Prevention and Recovery

University of Alabama Hospital

Phase 3

Dothan, Alabama1 trial

Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation

SEC Clinical Research

Phase 2

Boston, Massachusetts1 trial

Apixaban in Thrombocytopenia

Beth Israel Deaconess Medical Center

Early 1

Syracuse, New York1 trial

Apixaban or Enoxaparin After Head and Neck Cancer Surgery

SUNY Upstate

Phase 4

Burlington, Vermont1 trial

Venous Thromboembolism Prevention in Outpatients With Glioma

University of Vermont Medical Center

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.